NCT04485416 (CCPO011) is a Phase 1 clinical trial of Eltrombopag in Solid Tumor, Childhood, sponsored by University of California, Davis.

Who is sponsoring NCT04485416?

NCT04485416 is sponsored by University of California, Davis.

What drugs are being tested in NCT04485416?

Interventions in NCT04485416: Eltrombopag.

What condition does NCT04485416 study?

NCT04485416 studies Solid Tumor, Childhood, Solid Tumor.

Is NCT04485416 still recruiting?

NCT04485416 is currently suspended. Last updated 10 April 2025.

Last reviewed 2025-04-10 · How we verify

NCT04485416: CCPO011

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Trial of Eltrombopag in Patients Undergoing Chemotherapy for Malignant Solid Tumors

Suspended Phase 1 Last updated 10 April 2025

What this trial tests

Phase 1 trial testing Eltrombopag in Solid Tumor, Childhood in 10 participants. Suspended.

Timeline

16 July 2021

Primary endpoint
17 May 2025

17 May 2025

Quick facts

Lead sponsor	University of California, Davis
Phase	Phase 1
Status	Suspended
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	10
Start date	16 July 2021
Primary completion	17 May 2025
Estimated completion	17 May 2025
Sites	1 location across United States

Drugs / interventions tested

Eltrombopag (ELTROMBOPAG) — full drug profile →

Conditions studied

Solid Tumor, Childhood — all drugs for Solid Tumor, Childhood →
Solid Tumor — all drugs for Solid Tumor →

Sponsor

University of California, Davis

Who can join

Adults 1 to 18, any sex, with Solid Tumor, Childhood or Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary Objective: To assess safety of eltrombopag in pediatric patients undergoing intensive chemotherapy for malignant solid tumors. Secondary Objectives: To assess the efficacy of eltrombopag in increasing platelet count up to 2 weeks after completion of chemotherapy in pediatric patients undergoing intensive chemotherapy for malignant solid tumors. Hypothesis: The hypothesis is that eltrombopag an oral thrombopoietin receptor agonist will increase the platelet count safely and efficaciously in children having chemotherapy induced thrombocytopenia while on therapy for solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Methyltransferase-like proteins in cancer biology and potential therapeutic targeting.
Qi YN, Liu Z, Hong LL, Li P, et al · · 2023 · cited 83× · PMID 37533128 · DOI 10.1186/s13045-023-01477-7
Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature.
Capecchi M, Serpenti F, Giannotta J, Pettine L, et al · · 2021 · cited 6× · PMID 34650908 · DOI 10.3389/fonc.2021.680411

Verify or expand the search:

Other trials of Eltrombopag

Trials testing the same drug.

NCT07189910 — Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP · Phase 4 · not yet recruiting
NCT07113743 — Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease · Phase 1, PHASE2 · enrolling by invitation
NCT07093606 — Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura · NA · recruiting
NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
NCT05653219 — A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia · Phase 3 · active not recruiting

Other recruiting trials for Solid Tumor, Childhood

Currently open trials in the same condition.

NCT05481502 — An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematol · NA · recruiting
NCT04471961 — Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia · NA · active not recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04485416 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 10 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04485416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing